Global GERD Market research

GERD Comprehensive Study by End Users (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral, Others), Drug Class (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro-Kinetic Agents, Others) Players and Region - Global Market Outlook to 2030

GERD Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About GERD
GERD or Gastroesophageal Reflux Disease, is a persistent condition characterized by the regular backflow of stomach acid into the esophagus, resulting in irritation and inflammation. This reflux can manifest through symptoms like heartburn, regurgitation, chest pain, and difficulty swallowing. Lifestyle adjustments, medications, and, in certain instances, surgical interventions are utilized to manage GERD. It is crucial for individuals encountering GERD symptoms to consult with healthcare professionals for accurate diagnosis and appropriate treatment. The GERD market is witnessing robust growth propelled by the surging global prevalence of Gastroesophageal Reflux Disease, coupled with heightened awareness among individuals about the condition and available treatment options. Advances in medical technology are playing a pivotal role in enhancing the identification and monitoring of GERD. Nonetheless, the market confronts challenges such as the potential side effects and constraints associated with current medications, elevated costs related to specific diagnostic procedures, and restricted reimbursement coverage for certain therapies. Noteworthy trends encompass the rising adoption of minimally invasive surgical techniques, a shift towards personalized medicine, and the integration of digital health solutions for remote patient monitoring. Opportunities abound in emerging markets with an increasing incidence of GERD, the innovation of diagnostic tools, expansion of pharmaceutical portfolios, and strategic investments in research for pioneering therapeutic approaches.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Key players maintain a strategic focus on the partnerships with other companies and also distribution expansion of various products in different geographies. Leading manufacturers of gastroesophageal reflux disease devices are also concentrating on technological innovation for the better treatment of gastroesophageal reflux diseases. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global GERD market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Haleon Group of Companies (United Kingdom), SRS Life Science (India), Johnson and Johnson (United States), Medtronic (Ireland), Pfizer,Inc. (United States), Reckitt Benckiser Group PLC (United Kingdom), Takeda Pharmaceutical Co.Ltd (Japan), Teva Pharmaceutical Industries Limited. (Israel) and TWi Pharmaceutical,Inc. (Taiwan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are AstraZeneca (United Kingdom), Zydus Group (India), Glenmark (India), Aurobindo Pharma (India), AstraZeneca (United Kingdom), Eisai (Japan) and GlaxoSmithKline (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global GERD market by and Region.



On the basis of geography, the market of GERD has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Hospitals will boost the GERD market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the GERD market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Antacids will boost the GERD market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing emphasis on personalized medicine and tailored treatment plans and Integration of digital health solutions for remote patient monitoring

Market Growth Drivers:
Rising healthcare expenditure and improved access to medical services and Lifestyle factors such as unhealthy diet and obesity contributing to the higher incidence of GERD

Challenges:
Variability in patient response to existing treatments and Impact of the global economic conditions on healthcare budgets and spending

Restraints:
Limited reimbursement coverage for specific GERD therapies and Patient non-compliance with prescribed treatments and lifestyle modifications

Opportunities:
Emerging markets with a rising incidence of GERD provide growth opportunities and Development of innovative diagnostic tools and technologies

Market Leaders and their expansionary development strategies
In August, 2022 Medtronic plc , a global leader in healthcare technology, announced that it has completed the acquisition of Affera, Inc. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution.The investigational Affera technology is designed to provide solutions for patients with cardiac arrhythmias such as atrial fibrillation. Through this acquisition Medtronic gains the Affera Prism-1™ cardiac mapping and navigation platform, which will be compatible with Medtronic and multiple, competitive therapeutic catheters and technologies.
In November 2023, Phathom Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal (GI) diseases, declared the commencement of U.S. commercial distribution for VOQUEZNA. This medication is now accessible for addressing adults diagnosed with Erosive Esophagitis, commonly known as Erosive Gastroesophageal Reflux Disease (GERD), and for providing relief from heartburn associated with Erosive GERD. Marking a significant milestone, VOQUEZNA is the inaugural and sole potassium-competitive acid blocker approved for use in the United States. This achievement introduces a novel class of acid suppression treatment to address a medical condition characterized by substantial unmet needs.


Key Target Audience
Investor, Research development, Research Industry, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End Users
  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers

By Route of Administration
  • Oral
  • Parenteral
  • Others

By Drug Class
  • Antacids
  • Proton Pump Inhibitors
  • H2 Receptor Blocker
  • Pro-Kinetic Agents
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising healthcare expenditure and improved access to medical services
      • 3.2.2. Lifestyle factors such as unhealthy diet and obesity contributing to the higher incidence of GERD
    • 3.3. Market Challenges
      • 3.3.1. Variability in patient response to existing treatments
      • 3.3.2. Impact of the global economic conditions on healthcare budgets and spending
    • 3.4. Market Trends
      • 3.4.1. Growing emphasis on personalized medicine and tailored treatment plans
      • 3.4.2. Integration of digital health solutions for remote patient monitoring
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global GERD, by End Users, Route of Administration, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global GERD (Value)
      • 5.2.1. Global GERD by: End Users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Diagnostic Centers
        • 5.2.1.3. Ambulatory Surgical Centers
      • 5.2.2. Global GERD by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Others
      • 5.2.3. Global GERD by: Drug Class (Value)
        • 5.2.3.1. Antacids
        • 5.2.3.2. Proton Pump Inhibitors
        • 5.2.3.3. H2 Receptor Blocker
        • 5.2.3.4. Pro-Kinetic Agents
        • 5.2.3.5. Others
      • 5.2.4. Global GERD Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. GERD: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Haleon Group of Companies (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. SRS Life Science (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson and Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer,Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Reckitt Benckiser Group PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Co.Ltd (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Limited. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. TWi Pharmaceutical,Inc. (Taiwan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global GERD Sale, by End Users, Route of Administration, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global GERD (Value)
      • 7.2.1. Global GERD by: End Users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Diagnostic Centers
        • 7.2.1.3. Ambulatory Surgical Centers
      • 7.2.2. Global GERD by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Others
      • 7.2.3. Global GERD by: Drug Class (Value)
        • 7.2.3.1. Antacids
        • 7.2.3.2. Proton Pump Inhibitors
        • 7.2.3.3. H2 Receptor Blocker
        • 7.2.3.4. Pro-Kinetic Agents
        • 7.2.3.5. Others
      • 7.2.4. Global GERD Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. GERD: by End Users(USD Million)
  • Table 2. GERD Hospitals , by Region USD Million (2018-2023)
  • Table 3. GERD Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 4. GERD Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 5. GERD: by Route of Administration(USD Million)
  • Table 6. GERD Oral , by Region USD Million (2018-2023)
  • Table 7. GERD Parenteral , by Region USD Million (2018-2023)
  • Table 8. GERD Others , by Region USD Million (2018-2023)
  • Table 9. GERD: by Drug Class(USD Million)
  • Table 10. GERD Antacids , by Region USD Million (2018-2023)
  • Table 11. GERD Proton Pump Inhibitors , by Region USD Million (2018-2023)
  • Table 12. GERD H2 Receptor Blocker , by Region USD Million (2018-2023)
  • Table 13. GERD Pro-Kinetic Agents , by Region USD Million (2018-2023)
  • Table 14. GERD Others , by Region USD Million (2018-2023)
  • Table 15. South America GERD, by Country USD Million (2018-2023)
  • Table 16. South America GERD, by End Users USD Million (2018-2023)
  • Table 17. South America GERD, by Route of Administration USD Million (2018-2023)
  • Table 18. South America GERD, by Drug Class USD Million (2018-2023)
  • Table 19. Brazil GERD, by End Users USD Million (2018-2023)
  • Table 20. Brazil GERD, by Route of Administration USD Million (2018-2023)
  • Table 21. Brazil GERD, by Drug Class USD Million (2018-2023)
  • Table 22. Argentina GERD, by End Users USD Million (2018-2023)
  • Table 23. Argentina GERD, by Route of Administration USD Million (2018-2023)
  • Table 24. Argentina GERD, by Drug Class USD Million (2018-2023)
  • Table 25. Rest of South America GERD, by End Users USD Million (2018-2023)
  • Table 26. Rest of South America GERD, by Route of Administration USD Million (2018-2023)
  • Table 27. Rest of South America GERD, by Drug Class USD Million (2018-2023)
  • Table 28. Asia Pacific GERD, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific GERD, by End Users USD Million (2018-2023)
  • Table 30. Asia Pacific GERD, by Route of Administration USD Million (2018-2023)
  • Table 31. Asia Pacific GERD, by Drug Class USD Million (2018-2023)
  • Table 32. China GERD, by End Users USD Million (2018-2023)
  • Table 33. China GERD, by Route of Administration USD Million (2018-2023)
  • Table 34. China GERD, by Drug Class USD Million (2018-2023)
  • Table 35. Japan GERD, by End Users USD Million (2018-2023)
  • Table 36. Japan GERD, by Route of Administration USD Million (2018-2023)
  • Table 37. Japan GERD, by Drug Class USD Million (2018-2023)
  • Table 38. India GERD, by End Users USD Million (2018-2023)
  • Table 39. India GERD, by Route of Administration USD Million (2018-2023)
  • Table 40. India GERD, by Drug Class USD Million (2018-2023)
  • Table 41. South Korea GERD, by End Users USD Million (2018-2023)
  • Table 42. South Korea GERD, by Route of Administration USD Million (2018-2023)
  • Table 43. South Korea GERD, by Drug Class USD Million (2018-2023)
  • Table 44. Taiwan GERD, by End Users USD Million (2018-2023)
  • Table 45. Taiwan GERD, by Route of Administration USD Million (2018-2023)
  • Table 46. Taiwan GERD, by Drug Class USD Million (2018-2023)
  • Table 47. Australia GERD, by End Users USD Million (2018-2023)
  • Table 48. Australia GERD, by Route of Administration USD Million (2018-2023)
  • Table 49. Australia GERD, by Drug Class USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific GERD, by End Users USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific GERD, by Route of Administration USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific GERD, by Drug Class USD Million (2018-2023)
  • Table 53. Europe GERD, by Country USD Million (2018-2023)
  • Table 54. Europe GERD, by End Users USD Million (2018-2023)
  • Table 55. Europe GERD, by Route of Administration USD Million (2018-2023)
  • Table 56. Europe GERD, by Drug Class USD Million (2018-2023)
  • Table 57. Germany GERD, by End Users USD Million (2018-2023)
  • Table 58. Germany GERD, by Route of Administration USD Million (2018-2023)
  • Table 59. Germany GERD, by Drug Class USD Million (2018-2023)
  • Table 60. France GERD, by End Users USD Million (2018-2023)
  • Table 61. France GERD, by Route of Administration USD Million (2018-2023)
  • Table 62. France GERD, by Drug Class USD Million (2018-2023)
  • Table 63. Italy GERD, by End Users USD Million (2018-2023)
  • Table 64. Italy GERD, by Route of Administration USD Million (2018-2023)
  • Table 65. Italy GERD, by Drug Class USD Million (2018-2023)
  • Table 66. United Kingdom GERD, by End Users USD Million (2018-2023)
  • Table 67. United Kingdom GERD, by Route of Administration USD Million (2018-2023)
  • Table 68. United Kingdom GERD, by Drug Class USD Million (2018-2023)
  • Table 69. Netherlands GERD, by End Users USD Million (2018-2023)
  • Table 70. Netherlands GERD, by Route of Administration USD Million (2018-2023)
  • Table 71. Netherlands GERD, by Drug Class USD Million (2018-2023)
  • Table 72. Rest of Europe GERD, by End Users USD Million (2018-2023)
  • Table 73. Rest of Europe GERD, by Route of Administration USD Million (2018-2023)
  • Table 74. Rest of Europe GERD, by Drug Class USD Million (2018-2023)
  • Table 75. MEA GERD, by Country USD Million (2018-2023)
  • Table 76. MEA GERD, by End Users USD Million (2018-2023)
  • Table 77. MEA GERD, by Route of Administration USD Million (2018-2023)
  • Table 78. MEA GERD, by Drug Class USD Million (2018-2023)
  • Table 79. Middle East GERD, by End Users USD Million (2018-2023)
  • Table 80. Middle East GERD, by Route of Administration USD Million (2018-2023)
  • Table 81. Middle East GERD, by Drug Class USD Million (2018-2023)
  • Table 82. Africa GERD, by End Users USD Million (2018-2023)
  • Table 83. Africa GERD, by Route of Administration USD Million (2018-2023)
  • Table 84. Africa GERD, by Drug Class USD Million (2018-2023)
  • Table 85. North America GERD, by Country USD Million (2018-2023)
  • Table 86. North America GERD, by End Users USD Million (2018-2023)
  • Table 87. North America GERD, by Route of Administration USD Million (2018-2023)
  • Table 88. North America GERD, by Drug Class USD Million (2018-2023)
  • Table 89. United States GERD, by End Users USD Million (2018-2023)
  • Table 90. United States GERD, by Route of Administration USD Million (2018-2023)
  • Table 91. United States GERD, by Drug Class USD Million (2018-2023)
  • Table 92. Canada GERD, by End Users USD Million (2018-2023)
  • Table 93. Canada GERD, by Route of Administration USD Million (2018-2023)
  • Table 94. Canada GERD, by Drug Class USD Million (2018-2023)
  • Table 95. Mexico GERD, by End Users USD Million (2018-2023)
  • Table 96. Mexico GERD, by Route of Administration USD Million (2018-2023)
  • Table 97. Mexico GERD, by Drug Class USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. GERD: by End Users(USD Million)
  • Table 108. GERD Hospitals , by Region USD Million (2025-2030)
  • Table 109. GERD Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 110. GERD Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 111. GERD: by Route of Administration(USD Million)
  • Table 112. GERD Oral , by Region USD Million (2025-2030)
  • Table 113. GERD Parenteral , by Region USD Million (2025-2030)
  • Table 114. GERD Others , by Region USD Million (2025-2030)
  • Table 115. GERD: by Drug Class(USD Million)
  • Table 116. GERD Antacids , by Region USD Million (2025-2030)
  • Table 117. GERD Proton Pump Inhibitors , by Region USD Million (2025-2030)
  • Table 118. GERD H2 Receptor Blocker , by Region USD Million (2025-2030)
  • Table 119. GERD Pro-Kinetic Agents , by Region USD Million (2025-2030)
  • Table 120. GERD Others , by Region USD Million (2025-2030)
  • Table 121. South America GERD, by Country USD Million (2025-2030)
  • Table 122. South America GERD, by End Users USD Million (2025-2030)
  • Table 123. South America GERD, by Route of Administration USD Million (2025-2030)
  • Table 124. South America GERD, by Drug Class USD Million (2025-2030)
  • Table 125. Brazil GERD, by End Users USD Million (2025-2030)
  • Table 126. Brazil GERD, by Route of Administration USD Million (2025-2030)
  • Table 127. Brazil GERD, by Drug Class USD Million (2025-2030)
  • Table 128. Argentina GERD, by End Users USD Million (2025-2030)
  • Table 129. Argentina GERD, by Route of Administration USD Million (2025-2030)
  • Table 130. Argentina GERD, by Drug Class USD Million (2025-2030)
  • Table 131. Rest of South America GERD, by End Users USD Million (2025-2030)
  • Table 132. Rest of South America GERD, by Route of Administration USD Million (2025-2030)
  • Table 133. Rest of South America GERD, by Drug Class USD Million (2025-2030)
  • Table 134. Asia Pacific GERD, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific GERD, by End Users USD Million (2025-2030)
  • Table 136. Asia Pacific GERD, by Route of Administration USD Million (2025-2030)
  • Table 137. Asia Pacific GERD, by Drug Class USD Million (2025-2030)
  • Table 138. China GERD, by End Users USD Million (2025-2030)
  • Table 139. China GERD, by Route of Administration USD Million (2025-2030)
  • Table 140. China GERD, by Drug Class USD Million (2025-2030)
  • Table 141. Japan GERD, by End Users USD Million (2025-2030)
  • Table 142. Japan GERD, by Route of Administration USD Million (2025-2030)
  • Table 143. Japan GERD, by Drug Class USD Million (2025-2030)
  • Table 144. India GERD, by End Users USD Million (2025-2030)
  • Table 145. India GERD, by Route of Administration USD Million (2025-2030)
  • Table 146. India GERD, by Drug Class USD Million (2025-2030)
  • Table 147. South Korea GERD, by End Users USD Million (2025-2030)
  • Table 148. South Korea GERD, by Route of Administration USD Million (2025-2030)
  • Table 149. South Korea GERD, by Drug Class USD Million (2025-2030)
  • Table 150. Taiwan GERD, by End Users USD Million (2025-2030)
  • Table 151. Taiwan GERD, by Route of Administration USD Million (2025-2030)
  • Table 152. Taiwan GERD, by Drug Class USD Million (2025-2030)
  • Table 153. Australia GERD, by End Users USD Million (2025-2030)
  • Table 154. Australia GERD, by Route of Administration USD Million (2025-2030)
  • Table 155. Australia GERD, by Drug Class USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific GERD, by End Users USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific GERD, by Route of Administration USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific GERD, by Drug Class USD Million (2025-2030)
  • Table 159. Europe GERD, by Country USD Million (2025-2030)
  • Table 160. Europe GERD, by End Users USD Million (2025-2030)
  • Table 161. Europe GERD, by Route of Administration USD Million (2025-2030)
  • Table 162. Europe GERD, by Drug Class USD Million (2025-2030)
  • Table 163. Germany GERD, by End Users USD Million (2025-2030)
  • Table 164. Germany GERD, by Route of Administration USD Million (2025-2030)
  • Table 165. Germany GERD, by Drug Class USD Million (2025-2030)
  • Table 166. France GERD, by End Users USD Million (2025-2030)
  • Table 167. France GERD, by Route of Administration USD Million (2025-2030)
  • Table 168. France GERD, by Drug Class USD Million (2025-2030)
  • Table 169. Italy GERD, by End Users USD Million (2025-2030)
  • Table 170. Italy GERD, by Route of Administration USD Million (2025-2030)
  • Table 171. Italy GERD, by Drug Class USD Million (2025-2030)
  • Table 172. United Kingdom GERD, by End Users USD Million (2025-2030)
  • Table 173. United Kingdom GERD, by Route of Administration USD Million (2025-2030)
  • Table 174. United Kingdom GERD, by Drug Class USD Million (2025-2030)
  • Table 175. Netherlands GERD, by End Users USD Million (2025-2030)
  • Table 176. Netherlands GERD, by Route of Administration USD Million (2025-2030)
  • Table 177. Netherlands GERD, by Drug Class USD Million (2025-2030)
  • Table 178. Rest of Europe GERD, by End Users USD Million (2025-2030)
  • Table 179. Rest of Europe GERD, by Route of Administration USD Million (2025-2030)
  • Table 180. Rest of Europe GERD, by Drug Class USD Million (2025-2030)
  • Table 181. MEA GERD, by Country USD Million (2025-2030)
  • Table 182. MEA GERD, by End Users USD Million (2025-2030)
  • Table 183. MEA GERD, by Route of Administration USD Million (2025-2030)
  • Table 184. MEA GERD, by Drug Class USD Million (2025-2030)
  • Table 185. Middle East GERD, by End Users USD Million (2025-2030)
  • Table 186. Middle East GERD, by Route of Administration USD Million (2025-2030)
  • Table 187. Middle East GERD, by Drug Class USD Million (2025-2030)
  • Table 188. Africa GERD, by End Users USD Million (2025-2030)
  • Table 189. Africa GERD, by Route of Administration USD Million (2025-2030)
  • Table 190. Africa GERD, by Drug Class USD Million (2025-2030)
  • Table 191. North America GERD, by Country USD Million (2025-2030)
  • Table 192. North America GERD, by End Users USD Million (2025-2030)
  • Table 193. North America GERD, by Route of Administration USD Million (2025-2030)
  • Table 194. North America GERD, by Drug Class USD Million (2025-2030)
  • Table 195. United States GERD, by End Users USD Million (2025-2030)
  • Table 196. United States GERD, by Route of Administration USD Million (2025-2030)
  • Table 197. United States GERD, by Drug Class USD Million (2025-2030)
  • Table 198. Canada GERD, by End Users USD Million (2025-2030)
  • Table 199. Canada GERD, by Route of Administration USD Million (2025-2030)
  • Table 200. Canada GERD, by Drug Class USD Million (2025-2030)
  • Table 201. Mexico GERD, by End Users USD Million (2025-2030)
  • Table 202. Mexico GERD, by Route of Administration USD Million (2025-2030)
  • Table 203. Mexico GERD, by Drug Class USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global GERD: by End Users USD Million (2018-2023)
  • Figure 5. Global GERD: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global GERD: by Drug Class USD Million (2018-2023)
  • Figure 7. South America GERD Share (%), by Country
  • Figure 8. Asia Pacific GERD Share (%), by Country
  • Figure 9. Europe GERD Share (%), by Country
  • Figure 10. MEA GERD Share (%), by Country
  • Figure 11. North America GERD Share (%), by Country
  • Figure 12. Global GERD share by Players 2023 (%)
  • Figure 13. Global GERD share by Players (Top 3) 2023(%)
  • Figure 14. Global GERD share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Haleon Group of Companies (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Haleon Group of Companies (United Kingdom) Revenue: by Geography 2023
  • Figure 18. SRS Life Science (India) Revenue, Net Income and Gross profit
  • Figure 19. SRS Life Science (India) Revenue: by Geography 2023
  • Figure 20. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson and Johnson (United States) Revenue: by Geography 2023
  • Figure 22. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 24. Pfizer,Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer,Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Reckitt Benckiser Group PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Reckitt Benckiser Group PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 28. Takeda Pharmaceutical Co.Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Takeda Pharmaceutical Co.Ltd (Japan) Revenue: by Geography 2023
  • Figure 30. Teva Pharmaceutical Industries Limited. (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Limited. (Israel) Revenue: by Geography 2023
  • Figure 32. TWi Pharmaceutical,Inc. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 33. TWi Pharmaceutical,Inc. (Taiwan) Revenue: by Geography 2023
  • Figure 34. Global GERD: by End Users USD Million (2025-2030)
  • Figure 35. Global GERD: by Route of Administration USD Million (2025-2030)
  • Figure 36. Global GERD: by Drug Class USD Million (2025-2030)
  • Figure 37. South America GERD Share (%), by Country
  • Figure 38. Asia Pacific GERD Share (%), by Country
  • Figure 39. Europe GERD Share (%), by Country
  • Figure 40. MEA GERD Share (%), by Country
  • Figure 41. North America GERD Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Haleon Group of Companies (United Kingdom)
  • SRS Life Science (India)
  • Johnson and Johnson (United States)
  • Medtronic (Ireland)
  • Pfizer,Inc. (United States)
  • Reckitt Benckiser Group PLC (United Kingdom)
  • Takeda Pharmaceutical Co.Ltd (Japan)
  • Teva Pharmaceutical Industries Limited. (Israel)
  • TWi Pharmaceutical,Inc. (Taiwan)
Additional players considered in the study are as follows:
AstraZeneca (United Kingdom) , Zydus Group (India) , Glenmark (India) , Aurobindo Pharma (India) , AstraZeneca (United Kingdom) , Eisai (Japan) , GlaxoSmithKline (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 214 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global GERD Market research Quantitative research analysis
Global GERD Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Haleon Group of Companies (United Kingdom), SRS Life Science (India), Johnson and Johnson (United States), Medtronic (Ireland), Pfizer,Inc. (United States), Reckitt Benckiser Group PLC (United Kingdom), Takeda Pharmaceutical Co.Ltd (Japan), Teva Pharmaceutical Industries Limited. (Israel) and TWi Pharmaceutical,Inc. (Taiwan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing emphasis on personalized medicine and tailored treatment plans " is seen as one of major influencing trends for GERD Market during projected period 2023-2030.
The GERD market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global GERD Market research Report?

Have a Query? Click Here

Other Related Reports

CO2 Incubators Comprehensive Study by Type (Water Jacketed CO2 Incubators, Air-Jacketed CO2 Incubators, Direct Heat CO2 Incubators), Application (Industrial, Biotechnology, Agriculture, Others), Capa...
$ 3450
Gout Drugs Comprehensive Study by Type (Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Others), Application (Clinic, Hos...
$ 3650
Varicose veins treatment Comprehensive Study by Treatment (Surgery, Ligation and Stripping, Sclerotherapy, Radiofrequency Ablation, Endovenous Laser Treatment, Transilluminated Powered Phlebectomy), ...
$ 3750
Basal Cell Nevus Syndrome Drug Comprehensive Study by Type (Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene, Others), Application (Clinic, Hospital, Others), Drugs (Aldara (Imiqu...
$ 3650
Autoimmune Disease Diagnosis Comprehensive Study by Type (Rheumatoid arthritis, Lupus, Coeliac disease, Type 1 diabetes, Others), End Users (Hospitals, Clinics, Pharmaceutical Companies, Government R...
$ 3750
Mycoplasma Testing Comprehensive Study by Type (Instruments, Kits & Reagents (Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other), Services), Applicati...
$ 3750